Canaccord Genuity Reaffirms Buy Rating on Edwards Lifesciences (EW)
A number of other firms have also recently commented on EW. Analysts at Goldman Sachs (NYSE: GS) raised their price target on shares of Edwards Lifesciences from $90.00 to $97.00 in a research note to investors on Wednesday, May 2nd. They now have a “buy” rating on the stock. Separately, analysts at Wells Fargo & Co. (NYSE: WFC) upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating in a research note to investors on Wednesday, May 2nd. Finally, analysts at GARP Research reiterated a “buy” rating on shares of Edwards Lifesciences in a research note to investors on Monday, April 30th.
Shares of Edwards Lifesciences opened at 81.89 on Friday. Edwards Lifesciences has a one year low of $61.59 and a one year high of $91.50. The company has a market cap of $9.384 billion and a P/E ratio of 40.97.
Edwards Lifesciences Corporation (Edwards Lifesciences) is engaged in the science of heart valves and hemodynamic monitoring.